Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 207127 with faldaprevir and ribavirin in genotype 1b chronic hepatitis C with moderate hepatic impairment
2012-003534-17Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing BI 207127 + faldaprevir + ribavirin with Placebo + faldaprevir + ribavirin (2 arms). Primary endpoint: Sustained virologic response at Week 12 post-treatment. Started Jan 2013; status: completed.
02
Drugs
deleobuvirfaldaprevirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-003534-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003534-17.